File this under ‘unintended consequences.’
A number of health care organizations are complaining that a final guideline the US Food and Drug Administration recently released for naming both biologic medicines and identical, but lower-cost biosimilar versions will cost the health care system billions of dollars in technology costs.
About the Author Reprints
